Literature DB >> 11224098

Subjective and psychomotor effects of nitrous oxide in healthy volunteers.

C.S. Dohrn1, J.L. Lichtor, R.S. Finn, A. Uitvlugt, D.W. Coalson, G. Rupani, H. de Wit, J.P. Zacny.   

Abstract

The effects of nitrous oxide at subanesthetic doses (0%, 10%, 20%, and 40% in oxygen) on mood and psychomotor performance were determined in a group of 12 healthy volunteers (six males and six females). A randomized, placebo-controlled, double-blinded, crossover trial of five experimental sessions was used. Effects were measured before, during and after a 30-min inhalation period of the agent, using three subjective effects questionnaires (the Profile of Mood States, the Addiction Research Center Inventory, and the Visual Analogue Scale); and two psychomotor tests (auditory reaction time and Digit Symbol Substitution Test). In addition, an End-of-Session questionnaire, administered 60min after cessation of inhaling the agent, was used, which measured the subjects' reactions to the agent inhaled that day (i.e. peak concentration effect and concentration liking). The primary effects observed from nitrous oxide were confined to the inhalation of 20% and 40% concentrations. Subjects became more confused, sedated, high, dysphoric, and stimulated during inhalation of 40% nitrous oxide; fatigue, depression and anxiety increased after inhalation of 40% nitrous oxide had ceased. Significant or near-significant differences on several measures of subjective effects emerged between sexes. On the End-of-Session questionnaire, subjects' ratings of the peak effect of nitrous oxide were dose-related. There was individual variation in the degree to which subjects liked nitrous oxide: eight of the 12 subjects reported liking the 40% concentration, one was neutral, and three did not like it. Subjects' performance on the DSST was significantly impaired during inhalation of 40% nitrous oxide, but recovered soon after inhalation stopped. In summary, nitrous oxide had robust effects on mood, there appeared to be sex differences in the magnitude of subjective effects of nitrous oxide, and there was some variability in the extent to which subjects liked the anesthetic agent.

Entities:  

Year:  1992        PMID: 11224098     DOI: 10.1097/00008877-199203010-00005

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  6 in total

1.  Lack of sex differences to the subjective effects of nitrous oxide in healthy volunteers.

Authors:  James P Zacny; Jenny M Jun
Journal:  Drug Alcohol Depend       Date:  2010-07-25       Impact factor: 4.492

2.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  The subjective, behavioral and cognitive effects of subanesthetic concentrations of isoflurane and nitrous oxide in healthy volunteers.

Authors:  J P Zacny; G Sparacino; P Hoffmann; R Martin; J L Lichtor
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

4.  Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers.

Authors:  Sandra D Comer; Ziva D Cooper; William J Kowalczyk; Maria A Sullivan; Suzette M Evans; Adam M Bisaga; Suzanne K Vosburg
Journal:  Psychopharmacology (Berl)       Date:  2009-10-27       Impact factor: 4.530

5.  Discriminative stimulus effects of nitrous oxide in mice: comparison with volatile hydrocarbons and vapor anesthetics.

Authors:  Kellianne J Richardson; Keith L Shelton
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

6.  Rewarding Subjective Effects of the NMDAR Antagonist Nitrous Oxide (Laughing Gas) Are Moderated by Impulsivity and Depressive Symptoms in Healthy Volunteers.

Authors:  Sunjeev K Kamboj; Hannah Zhao; Luzia Troebinger; Giulia Piazza; Emma Cawley; Vanessa Hennessy; Georges Iskandar; Ravi K Das
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.